IP Library › Granted Patent US 8,609,816

Granted Patent B2

US 8,609,816 · App. 12/092,866 · Granted Dec 17, 2013

Human monoclonal antibodies to O8E

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 8,609,816
App. No.: 12/092,866
Granted: Dec 17, 2013
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.

Claims (93)

1. An isolated human monoclonal antibody or antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof cross-competes for binding to O8E with a reference antibody or reference antigen-binding portion thereof comprising:

(a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 1 and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 6;

(b) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 2 and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 7;

(c) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 3 and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 8;

(d) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 4 and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 9; or

(e) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 5 and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 10.

2. The antibody or antigen-binding portion thereof of claim 1 , wherein the antibody or antigen-binding portion thereof is internalized upon binding to its antigen.

3. The antibody or antigen-binding portion thereof of claim 1 , wherein the antibody or antigen-binding portion thereof binds to a breast cell carcinoma tumor cell line, the breast cell carcinoma tumor cell line being SKBR3 cell line.

4. The antibody or antigen-binding portion thereof of claim 1 , wherein the antibody or antigen-binding portion thereof lacks fucose residues.

5. The antibody or antigen-binding portion thereof of claim 1 , wherein the reference antibody or reference antigen-binding portion thereof comprises:

(a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 1; and

(b) a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 6.

6. The antibody or antigen-binding portion thereof of claim 1 , wherein the reference antibody or reference antigen-binding portion thereof comprises:

(a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 2; and

(b) a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 7.

7. The antibody or antigen-binding portion thereof of claim 1 , wherein the reference antibody or reference antigen-binding portion thereof comprises:

(a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 3; and

(b) a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 8.

8. The antibody or antigen-binding portion thereof of claim 1 , wherein the reference antibody or reference antigen binding portion thereof comprises:

(a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 4; and

(b) a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 9.

9. The antibody or antigen-binding portion thereof of claim 1 , wherein the reference antibody or reference antigen binding portion thereof comprises:

(a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 5; and

(b) a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 10.

10. An isolated monoclonal antibody, or antigen-binding portion thereof, comprising a heavy chain variable region that comprises CDR1, CDR2, and CDR3 domains; and a light chain variable region that comprises CDR1, CDR2, and CDR3 domains, wherein the heavy chain variable region and light chain variable region CDR1, CDR2, and CDR3 domains are selected from the group consisting of:

(a) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:11; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:16; a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:21; a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:26; a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:31; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:36;

(b) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:12; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:17; a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:22; a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:27; a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:32; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:37;

(c) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:13; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:18; a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:23; a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:28; a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:33; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:38;

(d) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:14; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:19; a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:24; a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:29; a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:34; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:39; and

(e) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:15; a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:20; a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:25; a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:30; a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:35; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:40;

wherein the antibody or antigen-binding portion thereof specifically binds to 08E.

11. The antibody or antigen-binding portion thereof of claim 10 , which comprises:

a) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 11;

b) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 16;

c) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 21;

d) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 26;

e) a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 31; and

f) a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 36.

12. The antibody or antigen-binding portion thereof of claim 10 , which comprises:

a) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 12;

b) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 17;

c) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 22;

d) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 27;

e) a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 32; and

f) a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 37.

13. The antibody or antigen-binding portion thereof of claim 10 , which comprises:

a) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 13;

b) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 18;

c) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 23;

d) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 28;

e) a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 33; and

f) a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 38.

14. The antibody or antigen-binding portion thereof of claim 10 , which comprises:

a) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 14;

b) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 19;

c) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 24;

d) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 29;

e) a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 34; and

f) a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 39.

15. The antibody or antigen-binding portion thereof of claim 10 , which comprises:

a) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 15;

b) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 20;

c) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 25;

d) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 30;

e) a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 35; and

f) a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 40.

16. An isolated monoclonal antibody, or antigen binding portion thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and light chain variable region are selected from the group consisting of:

(a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:1; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:6;

(b) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:2; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:7;

(c) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:3; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:8;

(d) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:4; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:9; and

(e) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:5; and a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO:10;

wherein the antibody or antigen-binding portion thereof specifically binds to 08E.

17. The antibody or antigenbinding portion thereof of claim 16 , comprising:

a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 1; and

b) a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 6.

18. The antibody or antigen-binding portion thereof of claim 16 , comprising:

a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 2; and

b) a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 7.

19. The antibody or antigen-binding portion thereof of claim 16 , comprising:

a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 3; and

b) a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 8.

20. The antibody or antigen-binding portion thereof of claim 16 , comprising:

a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 4; and

b) a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 9.

21. The antibody or antigen-binding portion thereof of claim 16 , comprising:

a) a heavy chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 5; and

b) a light chain variable region comprising amino acids having the sequence set forth in SEQ ID NO: 10.

22. An immunoconjugate comprising the antibody or antigen-binding portion thereof, of claim 1 , linked to a therapeutic agent.

23. A composition comprising the immunoconjugate of claim 22 and a pharmaceutically acceptable carrier.

24. The immunoconjugate of claim 22 , wherein the therapeutic agent is a cytotoxin.

25. The immunoconjugate of claim 22 , wherein the therapeutic agent is a radioactive isotope.

26. An immunoconjugate comprising the antibody, or antigen-binding portion thereof, of claim 18 , linked to a therapeutic agent.

Assignments (3)

MERGER Recorded Mar 19, 2015

From: MEDAREX, L.L.C.

To: E. R. SQUIBB & SONS, L.L.C.

Reel/Frame 035226/0690 →

MERGER Recorded Jun 13, 2013

From: MEDAREX, INC.

To: MEDAREX, L.L.C.

Reel/Frame 030603/0924 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 28, 2009

From: KORMAN, ALAN J.; SELBY, MARK J.; LU, LI-SHENG; WITTE, ALISON; HUANG, HAICHUN

To: MEDAREX, INC.

Reel/Frame 022745/0414 →